文献速递乳腺癌放疗

内乳淋巴结照射剂量与内乳淋巴结复发及总生存的配对病例对照研究

A Matched Case-Control Study of the Relationship Between Radiation Dose to the Internal Mammary Lymph Nodes and Clinical Outcomes in Patients With and Without Internal Mammary Lymph Node Relapses.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-02-20

基于人群数据库的配对病例对照研究,70例内乳淋巴结复发(IMNR)患者按1:2匹配140例无复发对照,中位随访9.1年。多变量分析显示治疗性内乳淋巴结照射≥40 Gy与更低的IMNR风险(HR 0.36)和更好的总生存(HR 0.49)相关。

要点

  • 治疗性内乳淋巴结照射≥40 Gy与更低的IMNR风险相关(HR 0.36,P=.009)。
  • 治疗性内乳淋巴结照射≥40 Gy与更好的总生存相关(HR 0.49,P=.02)。
  • 乳房切除术后IMNR风险更高(HR 2.11,P=.02)。

核心结论

  • 治疗性内乳淋巴结照射≥40 Gy与更低的IMNR风险和更好的总生存相关。

研究设计与样本

  • 在基于人群的数据库中识别2005年至2014年间接受治愈性治疗并随后发生IMNR的患者,按患者和肿瘤特征以1:2匹配无IMNR对照。

主要发现

  • 共70例IMNR病例匹配140例对照,中位随访9.1年,中位肿瘤大小25 mm,N分期为37% N0、33% N1、30% N2-3。
  • IMN剂量中位数病例组为4.1 Gy vs 对照组为13.7 Gy(P<.001)。
  • 多变量分析中,更差的IMNR与乳房切除相关(HR 2.11,P=.02),更好的IMNR与治疗性IMN照射相关(HR 0.36,P=.009)。
  • 更差的总生存与更大肿瘤尺寸(HR 1.02,P=.006)、≥10枚阳性腋窝淋巴结(HR 3.15,P=.04)和三阴性亚型(HR 2.92,P=.03)相关,更好的总生存与治疗性IMN照射相关(HR 0.49,P=.02)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Early Breast Cancer Trialists' Collaborative Group's 2023 meta-analysis of radiation therapy to regional nodes in early breast cancer demonstrated a significant improvement in overall survival (OS) without an associated improvement in locoregional recurrence in the trials comparing internal mammary node (IMN) irradiation versus none. We aimed to study cases with IMN relapse (IMNR) and controls without IMNR to examine the link between IMNR and OS. METHODS AND MATERIALS: Patients treated curatively between 2005 and 2014, who subsequently developed IMNR, were identified in a population-based database. The IMNR cases were matched 1:2 to controls without IMNR using patient and tumor characteristics. The internal mammary vessels in the first 3 intercostal spaces were outlined on planning computed tomography scans as the IMN clinical target volume, and the mean equivalent doses in 2-Gy fractions to the IMNs were calculated. Multivariable Fine and Gray competing-risk regression and Cox regression were used to evaluate the effect of the baseline patient, tumor, and treatment variables, including therapeutic IMN irradiation with ≥40 Gy on IMNR and OS. RESULTS: Seventy cases were matched with 140 controls. Median follow-up was 9.1 years, median tumor size was 25 mm, and N-stages were: 37% N0, 33% N1, and 30% N2-3. The medians of the IMN doses were 4.1 Gy for cases and 13.7 Gy for controls (P < .001). On multivariable analysis, worse IMNR was associated with mastectomy (hazard ratio [HR], 2.11; P = .02), and better IMNR was associated with therapeutic IMN irradiation (HR, 0.36; P = .009); worse OS was associated with larger tumor size (HR, 1.02; P = .006), ≥10 positive axillary nodes (HR, 3.15; P = .04), and triple-negative subtype (HR, 2.92; P = .03), and better OS was associated with therapeutic IMN irradiation (HR, 0.49; P = .02). CONCLUSIONS: We demonstrated that therapeutic IMN irradiation with ≥40 Gy was associated with both a lower risk of IMNR and improved OS.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nichol A, Wade L, Gondara L, et al. A Matched Case-Control Study of the Relationship Between Radiation Dose to the Internal Mammary Lymph Nodes and Clinical Outcomes in Patients With and Without Internal Mammary Lymph Node Relapses. Int J Radiat Oncol Biol Phys. 2025. PMID: 39986486. doi:10.1016/j.ijrobp.2025.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。